News | August 03, 2024
Eris Lifesciences posts Q1 FY25 at Rs. 89 Cr
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
The discussion at the fourth session was centered on the fusion of academic rigor and industrial pragmatism as a key to pioneering solutions for sustainable and prosperous future
This transaction is the third acquisition by three different Japanese players in this segment
Utidelone can penetrate BBB due to its unique physicochemical characteristics and insusceptibility to P-glycoprotein-mediated efflux
AIIMS Jammu is a beacon of hope not only for the people of J&K, but also for that of Leh, and other neighboring states
DKSH’s Business Unit Consumer Goods further capitalizes on its position to strengthen the consumer health, nutrition, and baby care categories
PEKK is a high-performance polymer family used in aerospace and other demanding markets
_256_384.jpg)
Cipla had earlier invested € 15 million in Ethris in 2022
Abdel has held leadership positions at Bayer, Merck, Catalent, Lonza, and KBI Biopharma,
Fischer MVL envisages to offer a diverse portfolio of diagnostic solutions
Subscribe To Our Newsletter & Stay Updated
